78712-43-3
Ozagrel hydrochloride
CAS: 78712-43-3
Molecular Formula: C13H13ClN2O2
78712-43-3 - Names and Identifiers
78712-43-3 - Physico-chemical Properties
| Molecular Formula | C13H13ClN2O2 |
| Molar Mass | 264.71 |
| Melting Point | 214-217° |
| Solubility | H2O: soluble |
| Appearance | solid |
| Color | white to off-white |
| Merck | 14,6980 |
| Storage Condition | under inert gas (nitrogen or Argon) at 2-8°C |
| Stability | Stable for 2 years from date of purchase as supplied. Solutions in distilled water may be stored at -20° for up to 1 month. |
| In vivo study | In Guinea Pigs, Ozagrel prevents oleic acid (OA)-induced thromboxane A(2) production and subsequent increases in total protein concentration and macrophage and neutrophil numbers in bronchopulmonary lavage fluid, and increased expression of monocyte chemoattractant protein -1 and interleukin-8 mRNA in the whole lung. Ozagrel (3 mg/kg) reduced the area and volume of cortical infarction after middle cerebral artery occlusion and reperfusion in rats. Ozagrel also has an inhibitory effect on neurological deficits in a rat model of microthrombosis. Ozagrel ameliorates degenerated spontaneous motor activity and motor coordination obstruction in a conscious mouse model of cerebral ischemia-reperfusion. In cats, Ozagrel inhibited the decrease in the specific gravity of brain tissue induced by occlusion-reperfusion in the SHR model of cerebral ischemia-reperfusion, and restored the decrease in cerebral cortex PO(2) after middle cerebral artery occlusion-reperfusion. Ozagrel also increases levels of 6-keto-PGF(1alpha), a prostaglandin I(2) (PGI(2)) metabolite in brain tissue after cerebral ischemia-reperfusion, whereas PGI(2) administration increases decreased spontaneous locomotor activity in a conscious mouse model of cerebral ischemia-reperfusion. In Guinea Pigs, Ozagrel was administered intravenously 30 minutes prior to the injection of oleic acid to prevent Pao(2) reduction and pulmonary vascular hyperpermeability. In Guinea Pigs, Ozagrel also protects against lactate dehydrogenase activity, a measure of lung cell damage, TXB(2), and its association with 6-keto-prostaglandin F(1α) in bronchoalveolar lavage fluid the increase in the proportion. |
78712-43-3 - Risk and Safety
| UN IDs | 3077 |
| WGK Germany | 2 |
| RTECS | UD3380000 |
| HS Code | 29332900 |
78712-43-3 - Nature
Open Data Verified Data
crystallized from ethanol-ether, melting point 214-217 °c.
Last Update：2024-01-02 23:10:35
78712-43-3 - Use
Open Data Verified Data
developed by nipponao Pharmaceutical Industry Co., Ltd., was first launched in Japan in April 1988. Potent thromboxane synthase inhibitors. By inhibiting thromboxane synthase, lowering thromboxane A2(TXA2) in vivo, and promoting the production of prostacyclin (PGI2), to fight against the aggregation of platelets and spasm of cerebral vessels, however, it had little effect on other arachidonic acid metabolizing enzymes such as cyclooxygenase. For the improvement of vasospasm after subarachnoid hemorrhage surgery and its complicated cerebral ischemia symptoms.
Last Update：2022-01-01 09:23:43
78712-43-3 - Safety
Open Data Verified Data
male and female mice, male and female rats LD50 (mg/kg): 1940, 1580, 1150, 1300 intravenous injection; 3800, 3600, 5900, 5700 oral; 2450, 2250, 0.
Last Update：2022-01-01 09:23:43
Supplier List
Product Name: Ozagrelhydrochloride Visit Supplier Webpage Request for quotation
CAS: 78712-43-3
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
CAS: 78712-43-3
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
Product Name: Ozagrelhydrochloride Visit Supplier Webpage Request for quotation
CAS: 78712-43-3
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
CAS: 78712-43-3
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
View History